RayKnowChina Research Map
Shortlist

BeijingCapital Medical University

Beijing Tiantan Hospital

首都医科大学附属北京天坛医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Tiantan Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Chordoma脊索瘤14 papers led
  2. Osteosarcoma骨肉瘤0 papers led
  3. Neuroblastoma神经母细胞瘤0 papers led
  4. Haemophilia A血友病 A1 paper led
  5. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病34 papers led2 open trials led
  6. Myasthenia gravis重症肌无力1 paper led
  7. Moyamoya disease烟雾病60 papers led9 open trials led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎6 papers led
  9. Takayasu arteritis大动脉炎1 paper led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
  12. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  13. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  14. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  15. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Chordoma

脊索瘤

Led 14 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 13.3%.

Papers led
14
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 3320232024: 2220242025: 332025

11 hospitals in Beijing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery
Papers it led14
  1. Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers.2025ACS applied materials & interfaces
  2. Development and validation of basement membrane-related signatures for predicting postoperative recurrence, tumor microenvironment and drug candidates in chordomas.2025BMC cancer
  3. Radiogenomic method combining DNA methylation profiles and magnetic resonance imaging radiomics predicts patient prognosis in skull base chordoma.2025Clinical epigenetics
  4. Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma.2024Neuro-oncology
  5. The novel developed and validated multiparametric MRI-based fusion radiomic and clinicoradiomic models predict the postoperative progression of primary skull base chordoma.2024Scientific reports
  6. Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma.2023BMC cancer
  7. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.2023Clinical and translational medicine
  8. Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  9. Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.2022Neurosurgical review
  10. Survival and treatment of cranial and spinal chordomas: a population-based study.2022Neurosurgical review
  11. TGFB3 downregulation causing chordomagenesis and its tumor suppression role maintained by Smad7.2021Carcinogenesis
  12. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5.2021Cell death & disease
  13. Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.2021Cell proliferation
  14. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.2021Nature communications
Earlier papers (2016–2020)30
  1. MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.2020AJNR. American journal of neuroradiology
  2. LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.2020Aging
  3. Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study.2020BMC cancer
  4. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.2020Journal of neurosurgery
  5. A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes.2020Neurology India
  6. Natural Growth Dynamics of Untreated Skull Base Chordomas In Vivo.2020World neurosurgery
  7. Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.2019Journal of clinical pathology
  8. Combination of PARP inhibitor and temozolomide to suppress chordoma progression.2019Journal of molecular medicine (Berlin, Germany)
  9. High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas.2019World neurosurgery
  10. Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review.2019World neurosurgery
  11. SNF5 as a prognostic factor in skull base chordoma.2018Journal of neuro-oncology
  12. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.2018Neuro-oncology
  13. Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas.2018World neurosurgery
  14. MR Imaging Grading System for Skull Base Chordoma.2017AJNR. American journal of neuroradiology
  15. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.2017Acta neurochirurgica
  16. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.2017Journal of neurosurgery
  17. In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".2017World neurosurgery
  18. In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".2017World neurosurgery
  19. In Reply to "Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature".2017World neurosurgery
  20. In Reply to "Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis".2017World neurosurgery
  21. Expression of Cathepsin K in Skull Base Chordoma.2017World neurosurgery
  22. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.2017World neurosurgery
  23. Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas.2017World neurosurgery
  24. Factors for Overall Survival in Patients with Skull Base Chordoma: A Retrospective Analysis of 225 Patients.2017World neurosurgery
  25. Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.2017World neurosurgery
  26. Factors for tumor progression in patients with skull base chordoma.2016Cancer medicine
  27. Bone invasiveness is associated with prognosis in clivus chordomas.2016Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  28. Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases.2016Neurosurgical review
  29. Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups.2016World neurosurgery
  30. Proposal and Validation of a Basic Progression Scoring System for Patients with Skull Base Chordoma.2016World neurosurgery
All its trials on ClinicalTrials.gov, any status1
  1. China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial AneurysmActive, not recruitingNCT07809178Lead (inferred)Start 2026-10

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 34 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 7.0%.

Papers led
34
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 101020212022: 4420222023: 4420232024: 9920242025: 662025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
    Phase
    Not given
    Started
    2019-01
    Registry
    NCT04106830

    Age 16 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  2. Enrolling by invitation
    Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06643858

    Age 6 years to 90 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  3. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  4. Recruiting
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    Phase
    Early phase 1
    Started
    2022-04
    Registry
    NCT05145361

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an

  5. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisImagingAcute attack treatment
Departments in papersNeurologyRadiology / nuclear medicinePathology / laboratory medicineNephrology
Papers it led34
  1. Serum GPR37 as a novel biomarker for disease activity, disability, and differential diagnosis in NMOSD.2026Clinica chimica acta; international journal of clinical chemistry
  2. Deep Gray Matter Iron Deposition in NMOSD and MOGAD: A Comparative Study with MS.2025Academic radiology
  3. Oligodendroglia in Neuromyelitis Optica Spectrum Disorder.2025Advances in neurobiology
  4. Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.2025BMC medicineFree full text
  5. Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.2025Frontiers in immunologyFree full text
  6. Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.2025Journal of magnetic resonance imaging : JMRI
  7. Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder.2025Multiple sclerosis and related disorders
  8. Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.2024AJNR. American journal of neuroradiologyFree full text
  9. Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.2024Annals of clinical and translational neurologyFree full text
  10. Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.2024Brain : a journal of neurology
  11. Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study.2024CNS neuroscience & therapeuticsFree full text
  12. The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry.2024CNS neuroscience & therapeuticsFree full text
  13. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.2024Journal of neuroimmunology
  14. Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.2024Journal of neurology
  15. Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders.2024Multiple sclerosis and related disorders
  16. APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model.2024Science translational medicine
  17. Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders.2023Frontiers in immunologyFree full text
  18. Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.2023Journal of neurology, neurosurgery, and psychiatry
  19. Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.2023Multiple sclerosis and related disorders
  20. Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  21. The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.2022BMC neurologyFree full text
  22. A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.2022Journal of clinical apheresis
  23. Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.2022Multiple sclerosis (Houndmills, Basingstoke, England)
  24. NMO-IgG Induce Interleukin-6 Release via Activation of the NF-κB Signaling Pathway in Astrocytes.2022Neuroscience
  25. Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunologyFree full text
  26. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.2021Journal of neurology, neurosurgery, and psychiatryFree full text
  27. Brain structural and functional alterations in MOG antibody disease.2021Multiple sclerosis (Houndmills, Basingstoke, England)
  28. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.2021Multiple sclerosis and related disorders
  29. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.2021Multiple sclerosis and related disorders
  30. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.2021Multiple sclerosis and related disorders
  31. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.2021Multiple sclerosis and related disorders
  32. Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.2021Multiple sclerosis and related disorders
  33. B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease.2021Neurology(R) neuroimmunology & neuroinflammationFree full text
  34. Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.2021Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsFree full text
Chinese-language papers (not in the count)2
  1. [Advancements and outstanding questions in neuroimmune diseases over the past decade].2024Zhonghua nei ke za zhi
  2. [Progress in the study of the correlation between dyslipidemia and demyelinating diseases of the nervous system].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status8
  1. Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)Enrolling by invitationNCT06643858Lead sponsorStart 2023-12
  2. Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)RecruitingNCT04106830Lead sponsorStart 2019-01
  3. Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen DeterminationStatus unknownNCT05414890Lead sponsorStart 2022-06
  4. China National Registry of Neuro-Inflammatory DiseasesStatus unknownNCT05154370Lead sponsorStart 2021-12
  5. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
  6. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  7. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Study siteEarly phase 1Start 2022-04
  8. A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersStatus unknownNCT06212245Study sitePhase 4Start 2024-02
More papers found outside PubMed (not counted)5
  1. Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS2025medRxivpreprint
  2. Development and Validation of a Differential Diagnostic Models for Guillain–Barré Syndrome Based on Clinical and Laboratory Indicators: A Retrospective Study2025Acta Neurologica Scandinavicaarticle
  3. Progress on single-cell sequencing technology in central nervous system autoimmune diseases2025DOAJ (DOAJ: Directory of Open Access Journals)article
  4. A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders2022bioRxiv (Cold Spring Harbor Laboratory)preprint
  5. Magnetic resonance imaging markers for multiple sclerosis and neuromyelitis optica spectrum disorders2021Neurology and Clinical Neurosciencearticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  2. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 60 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 16.9%.

Papers led
60
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 111120212022: 6620222023: 111120232024: 131320242025: 19192025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07889531

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  2. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  3. Recruiting
    Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06817434

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  4. Recruiting
    Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06832839

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  5. Recruiting
    Family-Based Moyamoya Susceptibility and Early Detection
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07517354

    Age not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

  6. Recruiting
    Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
    Phase
    Not given
    Started
    2023-10
    Registry
    NCT06041659

    Age 18 years to 65 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  7. Recruiting
    Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
    Phase
    Not given
    Started
    2022-05
    Registry
    NCT05332756

    Age 2 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  8. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

  9. Not yet recruiting
    Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07762547

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersNeurosurgeryRadiology / nuclear medicine
Papers it led60
  1. Integrated bulk RNA sequencing and mass cytometry analysis reveal the circulating immune landscape in ischemic and hemorrhagic Moyamoya disease.2025BMC immunologyFree full text
  2. Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.2025Brain and behaviorFree full text
  3. Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.2025CNS neuroscience & therapeuticsFree full text
  4. Taurine levels and long-term adverse cerebrovascular risk in moyamoya disease: A prognostic perspective study.2025Clinical nutrition (Edinburgh, Scotland)
  5. Innate Immune Cell Profiling in Peripheral Blood Mononuclear Cells of Patients with Moyamoya Disease.2025Inflammation
  6. Circulating T cell atlas in Moyamoya disease: insights into immunopathogenesis of cerebrovascular disorders.2025Journal of neuroinflammationFree full text
  7. Serum amyloid A2-induced phenotypic switching of vascular smooth muscle cells in moyamoya disease.2025Journal of neurosurgery
  8. Improvement in multiple cognitive domains via combined revascularization by 6 months' follow-up: a new potential surgical indication in moyamoya disease.2025Journal of neurosurgery
  9. RNF213 Variant and Infectious Burden Associated With Intracranial Artery Stenosis in Moyamoya Disease.2025Journal of the American Heart AssociationFree full text
  10. Comprehensive Analysis and In Vitro Verification of Endothelial-Mesenchymal Transition-Related Genes in Moyamoya Disease.2025Molecular neurobiology
  11. Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.2025Neurosurgical review
  12. Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.2025Orphanet journal of rare diseasesFree full text
  13. Deep-learning tool for early identification of non-traumatic intracranial hemorrhage etiology and application in clinical diagnostics based on computed tomography (CT) scans.2025PeerJFree full text
  14. Reorganization of gray matter networks in patients with Moyamoya disease.2025Scientific reportsFree full text
  15. Understanding external carotid artery collateralisation after cerebral revascularisation in moyamoya disease: insights from quantitative analysis.2025Stroke and vascular neurologyFree full text
  16. Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.2025Translational stroke research
  17. Alterations in the Glymphatic System and Association with Brain Structure and Cognitive Function in Moyamoya Disease.2025Translational stroke research
  18. Glymphatic Impairment Associated with Neurocognitive Dysfunction in Moyamoya Disease.2025Translational stroke research
  19. Age-Dependent Risk Factors for Hemorrhagic Events in Moyamoya Disease: The Role of Collateral Vessels.2025World neurosurgery
  20. Differential WNT4 expression among various subtypes of moyamoya disease results in alterations of microtubule stability.2024Clinical and translational medicineFree full text
  21. Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease.2024Clinical and translational medicineFree full text
  22. Association of lysine pathway metabolites with moyamoya disease.2024Clinical nutrition (Edinburgh, Scotland)
  23. Mass cytometry revealed the circulating immune cell landscape across different Suzuki stages of Moyamoya disease.2024Immunologic researchFree full text
  24. A novel system for evaluating collateralization of the external carotid artery after cerebral revascularization in moyamoya disease.2024Journal of neurosurgery
  25. Effectiveness of indirect revascularization for adult hemorrhagic moyamoya disease: a 10-year follow-up study.2024Journal of neurosurgery
  26. Nonalcoholic fatty liver disease is an independent risk factor for ischemic stroke after revascularization in patients with Moyamoya disease: a prospective cohort study.2024Lipids in health and diseaseFree full text
  27. Prognostic value of morphology and hemodynamics in moyamoya disease for long-term outcomes and disease progression.2024Scientific reportsFree full text
  28. Characterization of PANoptosis-related genes and the immune landscape in moyamoya disease.2024Scientific reportsFree full text
  29. A Vessel Wall MRI Investigation in Patients With Moyamoya or Quasi-Moyamoya Disease: Diagnosis, Features, and Outcomes.2024The Journal of craniofacial surgery
  30. Nomogram to Predict Good Neoangiogenesis After Indirect Revascularization Surgery in Patients with Moyamoya Disease: a Case-control Study.2024Translational stroke research
  31. Risk Factors for Specific Postoperative Ischemic Complications in Patients with Moyamoya Disease: A Single-Center Retrospective Study.2024Turkish neurosurgery
  32. Long-Term Clinical Outcomes After Cerebral Revascularization in Moyamoya Disease With Extracranial Internal Carotid Artery Occlusion.2024World neurosurgery
  33. The prognostic nutrition index is a predictor for long-term outcomes after revascularization in adult moyamoya disease.2023Acta neurochirurgica
  34. Association between systemic immune-inflammatory markers and the risk of moyamoya disease: a case-control study.2023Annals of medicineFree full text
  35. Integrated analysis of the association between methionine cycle and risk of moyamoya disease.2023CNS neuroscience & therapeuticsRCTFree full text
  36. Metabolomic signatures associated with pathological angiogenesis in moyamoya disease.2023Clinical and translational medicineFree full text
  37. Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.2023Current stem cell research & therapy
  38. Gut microbiota in adults with moyamoya disease: characteristics and biomarker identification.2023Frontiers in cellular and infection microbiologyFree full text
  39. RNA profiling of sEV (small extracellular vesicles)/exosomes reveals biomarkers and vascular endothelial dysplasia with moyamoya disease.2023Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFree full text
  40. Fetal posterior cerebral artery in pediatric and adult moyamoya disease: A single-center experience of 480 patients.2023Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  41. Association between DIAPH1 variant and posterior circulation involvement with Moyamoya disease.2023Scientific reportsFree full text
  42. Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease.2023Stroke
  43. Hemorrhage Risk in Moyamoya Disease with Fetal-Type Posterior Cerebral Artery: A Propensity Score-Matched Analysis.2023World neurosurgery
  44. Predictors of preoperative cognitive dysfunction in adults with Moyamoya disease: a preliminary research.2022BMC neurologyFree full text
  45. Recurrent Artery of Heubner Aneurysm Masquerading as Caudate Hemorrhage without Subarachnoid Hemorrhage in Moyamoya Disease: A Case Report and Literature Review.2022Current medical imaging
  46. Infarction Patterns and Recurrent Adverse Cerebrovascular Events in Moyamoya Disease.2022Disease markersFree full text
  47. Epigenome-Wide Association Study Reveals Differential Methylation Sites and Association of Gene Expression Regulation with Ischemic Moyamoya Disease in Adults.2022Oxidative medicine and cellular longevityFree full text
  48. Association of RNF213 Variants With Periventricular Anastomosis in Moyamoya Disease.2022Stroke
  49. Assessment of Surgical Outcomes in Children and Adult Ischemic Moyamoya Disease and Its Relationship with the Pre-infarction Cerebral Perfusion Status.2022Turkish neurosurgery
  50. Intraoperative transit-time ultrasonography combined with FLOW800 predicts the occurrence of cerebral hyperperfusion syndrome after direct revascularization of Moyamoya disease: a preliminary study.2021Acta neurochirurgica
  51. Risk factors for postoperative ischemic complications in pediatric moyamoya disease.2021BMC neurologyFree full text
  52. Changes of cerebral cortical structure and cognitive dysfunction in "healthy hemisphere" after stroke: a study about cortical complexity and sulcus patterns in bilateral ischemic adult moyamoya disease.2021BMC neuroscienceFree full text
  53. Impairments in brain perfusion, executive control network, topological characteristics, and neurocognition in adult patients with asymptomatic Moyamoya disease.2021BMC neuroscienceFree full text
  54. Clinical Implications of the "Brush Sign" in Susceptibility-Weighted Imaging for Moyamoya Disease.2021Cerebrovascular diseases (Basel, Switzerland)
  55. Assessment of blood supply of the external carotid artery in moyamoya disease using super-selective pseudo-continuous arterial spin labeling technique.2021European radiology
  56. Letter to the Editor Regarding "Clinical Prediction of Surgical Revascularization Outcome in Moyamoya Disease Via Transcranial Color Sonography".2021Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  57. Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.2021Neurosurgical review
  58. Intraoperative local hemodynamic quantitative analysis of direct revascularization in patients with moyamoya disease.2021Neurosurgical review
  59. Effects and safety of aspirin use in patients after cerebrovascular bypass procedures.2021Stroke and vascular neurologyFree full text
  60. Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings.2021Stroke and vascular neurologyFree full text
All its trials on ClinicalTrials.gov, any status17
  1. Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Not yet recruitingNCT07762547Lead sponsorN/AStart 2026-07
  2. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Lead sponsorStart 2026-08
  3. Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya DiseaseRecruitingNCT07889531Lead sponsorN/AStart 2026-10
  4. Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya DiseaseRecruitingNCT06832839Lead sponsorStart 2024-12
  5. Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya DiseaseRecruitingNCT06817434Lead sponsorStart 2024-12
  6. Family-Based Moyamoya Susceptibility and Early DetectionRecruitingNCT07517354Lead sponsorStart 2024-11
  7. Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under AnesthesiaRecruitingNCT06041659Lead sponsorStart 2023-10
  8. Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)RecruitingNCT05332756Lead sponsorStart 2022-05
  9. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Lead sponsorStart 2012-01
  10. Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization SurgeryStatus unknownNCT06051552Lead sponsorStart 2023-10
  11. Gut Microbiota in Patients With Moyamoya DiseaseStatus unknownNCT04890782Lead sponsorStart 2021-05
  12. The Role of m6A RNA Modification in Moyamoya DiseaseStatus unknownNCT04696094Lead sponsorStart 2021-01
  13. RNF213 Variants and Collateral Vessels in Moyamoya DiseaseCompletedNCT04906564Lead sponsorStart 2019-01
  14. Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease PatientsSuspendedNCT04064658Lead sponsorN/AStart 2019-10
  15. Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya DiseaseStatus unknownNCT02982135Lead (inferred)N/AStart 2016-01
  16. NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular EventsStatus unknownNCT04205578Study sitePhase 3Start 2020-01
  17. Precision Bypass in Patients With Moyamoya DiseaseWithdrawnNCT03516851Study siteN/AStart 2018-08
More papers found outside PubMed (not counted)7
  1. Divergent Phenotypes and Persistent Disability: A Comparative Cohort Study of Arterial Ischaemic and Haemorrhagic Stroke in Chinese Paediatric Patients2025Psycho-Oncologiearticle
  2. 甘油三酯-葡萄糖指数在烟雾病患者中的特征分析:1项病例对照研究(Analysis of Triglyceride-Glucose Index Characteristics in Patients with Moyamoya Disease: A Case-Control Study)2025DOAJ (DOAJ: Directory of Open Access Journals)article
  3. RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease2024Gene Reportsarticle
  4. Deep Learning Approach to Predict Hemorrhage in Moyamoya Disease2023arXiv (Cornell University)preprint
  5. Deep-Learning Tool for Early Identifying Non-Traumatic Intracranial Hemorrhage Etiology based on CT Scan2023arXiv (Cornell University)preprint
  6. Short⁃term neurological function and clinical symptom improvement after cerebral revascularization in adults with moyamoya disease: a single⁃center study2022DOAJ (DOAJ: Directory of Open Access Journals)article
  7. A Practical Questionnaire and Literature Review: Dose Suzuki Grading Still the Gold Standard for the Diagnosis of Moyamoya Disease?2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 6 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 2.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 112025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led6
  1. Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  2. Typical metabolic pattern of 18F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features.2023BMC neuroscience
  3. Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood‒brain barrier disruption in anti-NMDA receptor encephalitis.2023Journal of neuroinflammation
  4. Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.2022Acta neurologica Scandinavica
  5. The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.2022Acta neurologica Scandinavica
  6. Aberrant multimodal brain networks in patients with anti-NMDA receptor encephalitis.2021CNS neuroscience & therapeutics
Earlier papers (2016–2020)4
  1. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study.2020Medicine
  2. Reply.2018AJNR. American journal of neuroradiology
  3. Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome.2018AJNR. American journal of neuroradiology
  4. Paraneoplastic Anti-N-Methyl-D-Aspartic Acid Receptor Encephalitis.2017Chinese medical journal
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingNCT05503264Study sitePhase 3Start 2022-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06556394

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyNeurosurgery
Papers it led4
  1. The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.2026Neurodegenerative disease management
  2. Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk.2025Lipids in health and disease
  3. Amyotrophic lateral sclerosis and myasthenia gravis overlaps syndrome: a series of case report.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.2023Journal of biochemical and molecular toxicologyRCT
Earlier papers (2016–2020)2
  1. NEK1 and GRN mutations coexist in a sporadic Chinese Hui descent ALS patient.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Needle electromyography of the frontalis muscle in patients with amyotrophic lateral sclerosis.2016Muscle & nerve
All its trials on ClinicalTrials.gov, any status6
  1. Tofacitinib in Patients With Amyotrophic Lateral SclerosisNot yet recruitingNCT06689982Lead sponsorEarly phase 1Start 2024-12
  2. Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene MutationCompletedNCT05903690Lead sponsorEarly phase 1Start 2023-05
  3. Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral SclerosisStatus unknownNCT06181526Lead sponsorPhase 1Start 2023-12
  4. Amyotrophic Lateral Sclerosis RegistryStatus unknownNCT05892822Lead (inferred)Start 2023-06
  5. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene MutationRecruitingNCT06556394Study sitePhase 1Start 2024-12
  6. A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)Not yet recruitingNCT07833618Study sitePhase 2Start 2026-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT06421831

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 PatientsRecruitingNCT06421831Study sitePhase 1/Phase 2Start 2024-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Beijing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Beijing for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京天坛医院

Beijing Tiantan Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Neurosurgical Institute and Beijing Tiantan Hospital; Jing-Jin Center for Neuroinfalmmation Beijing Tiantan Hospital; Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University; A.L.) and Beijing Tiantan Hospital (F.P; Beijing Tiantan Hospital Capital Medical University; Beijing Tiantan Hospital Affiliated with Capital Medical University; Beijing Tiantan Hospital of Capital Medical University

Suggest a correctionDownload the data